At the time of writing, Jazz Pharmaceuticals plc [JAZZ] stock is trading at $123.16, up 1.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JAZZ shares have gain 2.16% over the last week, with a monthly amount glided 2.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on December 12, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $175 from $140. Previously, Goldman started tracking the stock with Buy rating on June 05, 2024, and set its price target to $169. On January 03, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $160 on the stock. UBS downgraded its rating to a Neutral and decreased its price target to $135 on November 27, 2023. Raymond James initiated its recommendation with a Mkt Perform. In a note dated December 09, 2022, Goldman upgraded an Buy rating on this stock and revised its target price from $192 to $190.
For the past year, the stock price of Jazz Pharmaceuticals plc fluctuated between $99.06 and $134.17. Currently, Wall Street analysts expect the stock to reach $182.75 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $123.16 at the most recent close of the market. An investor can expect a potential return of 48.38% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
According to Jazz Pharmaceuticals plc [NASDAQ:JAZZ], the company’s sales were 3.99B for trailing twelve months, which represents an 8.52% jump. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 120.15 points at the first support level, and at 117.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 124.94, and for the 2nd resistance point, it is at 126.72.
Ratios To Look Out For
It is important to note that Jazz Pharmaceuticals plc [NASDAQ:JAZZ] has a current ratio of 4.26. As well, the Quick Ratio is 3.74, while the Cash Ratio is 2.15. Considering the valuation of this stock, the price to sales ratio is 1.86, the price to book ratio is 1.78 and price to earnings (TTM) ratio is 17.74.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Chairman & CEO, that happened on Jan 02 ’25 when 1500.0 shares were sold. Officer, COZADD BRUCE C completed a deal on Jan 02 ’25 to buy 1500.0 shares. Meanwhile, Chairman & CEO COZADD BRUCE C sold 2000.0 shares on Dec 02 ’24.
